Besifloxacin/dexamethasone intracanalicular insert - Ocular Therapeutix
Alternative Names: OTX BSILatest Information Update: 28 Aug 2023
At a glance
- Originator Ocular Therapeutix
- Class Anti-inflammatories; Antibacterials; Antiemetics; Antineoplastics; Azepines; Carboxylic acids; Cyclopropanes; Eye disorder therapies; Fluorinated steroids; Fluoroquinolones; Glucocorticoids; Non-opioid analgesics; Pregnadienediols; Small molecules
- Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacterial infections; Inflammation; Postoperative pain
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Bacterial-infections in USA (Ophthalmic, Controlled release)
- 28 Aug 2023 No recent reports of development identified for preclinical development in Inflammation in USA (Ophthalmic, Controlled release)
- 28 Aug 2023 No recent reports of development identified for preclinical development in Postoperative-pain in USA (Ophthalmic, Controlled release)